Literature DB >> 12378999

Endovascular aneurysm treatment from the neurosurgeon's point of view.

Y Kaku1.   

Abstract

Recent advancement in microneurosurgery and interventional neuroradiology has brought us a new aspect in the treatment of cerebral aneurysms. There is now a choice of several therapeutic alternatives for the management of cerebral aneurysms. The selection of interventional neuroradiologic techniques with GDC therefore requires consideration of neurosurgical techniques, just as the selection of neurosurgical treatment requires an analysis of endovascular alternatives. The decision for treatment of an individual patient should be based on objective selection of the safest and the most effective treatment. It is self-evident that the primary consideration in the selection process must be the immediate and long-term welfare of the individual patient, rather than the physician's preference for any specific treatment modality. Although GDC embolization has been successful in preventing acute subsequent bleeding of aneurysms, incomplete endovascular occlusion of aneurysm leaves the patient at risk for future expansion and future subarachnoid hemorrhage. With this limitation in mind, patients need to be very carefully chosen for GDC embolization. Endovascular treatment of intracranial aneurysms with GDCs has thus been limited to adjuvant or palliative indications for many patients.

Entities:  

Mesh:

Year:  2002        PMID: 12378999     DOI: 10.1007/978-3-7091-6736-6_18

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  2 in total

1.  Comparison of Endovascular and Surgical Treatment for Ruptured Cerebral Aneurysms with respect to Short and Long-Term Outcome.

Authors:  K Fukui; O Suzuki; S Ito; M Miyazaki; K Hattori; H Osawa
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

2.  Treatment of cerebral aneurysms: surgical clipping and coil embolization.

Authors:  Y Kaku; H Watarai; J Kokuzawa; T Tanaka; T Andoh
Journal:  Interv Neuroradiol       Date:  2007-06-27       Impact factor: 1.610

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.